---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058186"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:34:47.051292+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio Q1 net loss $15.4M; cash $105M; IPO adds $100M; BBI-825 trial dosed

## Summary
- Net loss $15.4M in Q1 2024 vs $11.7M in Q1 2023; R&D expenses $13.1M vs $9.5M.
- Cash & investments $104.9M at March 31; April IPO grossed $100M from 6.25M shares, extending runway into 2H 2026.
- BBI-355 POTENTIATE trial advanced to Part 2 combining with EGFR or FGFR inhibitors in oncogene-amplified tumors.
- First patient dosed in BBI-825 Phase 1/2 STARMAP trial targeting resistance gene amplifications.

## SEC filing metadata
- accession: 0000950170-24-058186
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000095017024058186/0000950170-24-058186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000095017024058186/bold-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058186
- JSON: https://secwatch.observer/filing/0000950170-24-058186.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058186.txt

## Key facts
- Earnings Releases
  Boundless Bio, Inc. reported the quarter ended March 31, 2024 results: net income $15.4 million.
  - Period: the quarter ended March 31, 2024
  - Net income: $15.4 million
  - Result: reported results
  source text: Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782303/000095017024058186/0000950170-24-058186-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.